Osteoporosis Drugs Market shall reach a value of $10,804 Million in 2027, growing with a CAGR of 3.9% during the forecast period of 2020 to 2027.
The osteoporosis drug market is mainly driven by the widespread rise in the prevalence of this disorder worldwide. The unprecedented rise in the increased cases has resulted in the high demand for the drugs like prophylaxis and treatment of osteoporosis thus increasing the growth potential in the coming years. An upsurge in incidence as a result of menopause in women is anticipated to be the key contributing factor. It is estimated that Osteoporosis affects almost 200 million women globally. Osteoporosis is found in 2/3rd of women aged 90. 2/5th of women aged 80. 1/5th of women aged 70 and 1/10th of women aged 60. In addition, 1 in every 3 women over the age of 50 are found to experience osteoporotic fractures. It is also observed that Osteoporosis and other bone-related diseases can be associated with a sedentary lifestyle, alcohol abuse and smoking is found to promote the disease in men. The wide range of drugs in pipeline posses high chances of getting approved in clinical trials in future is predicted to provide good growth opportunities to osteoporosis market. Some imperative investigational drugs include Romosozumab, Biosozumab, ZP-PTH, ZP-034. The increased demand can also be a consequence of collaborative research initiatives and new product development by the major healthcare players consistently trying to improve the treatment alternatives and current market space. Investment in research funding by the key players will further propel the growth in the market. For instance, In Oct 2013, Pfizer Inc. announced the approval of DUAVEE, conjugated estrogen for the prevention and treatment of post-menopause osteoporosis. In Nov 2016, Dr Reddy’s laboratory announced to launch Raloxifene in the U.S. for treatment of Osteoporosis. By product, the bisphosphonates acquired the major share of the osteoporosis drugs market in 2018, due to the increased investments in R&D. Furthermore, bisphosphonates are commonly prescribed drugs for treatment of osteoporosis. Region-wise, North America has the largest share in the osteoporosis drugs market and is likely to continue the trend in future, but the Asia Pacific is estimated to have the fastest growth due to the increased awareness about the condition and also because of the increased medical tourism coupled with the increased focus and investment on healthcare by the government and concerned authorities.
Osteoporosis Drugs Market Competition
Key companies operating in this industry are Eli Lilly, Novartis, Pfizer, Amgen, Merck, Novo nordisk, Actavis, Roche, F. Hoffmann-La Roche AG, Radius Health, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.
• Osteoporosis Drugs Market Revenue Estimation and Forecast (2020 – 2027)
• Production Estimation and Forecast (2020 – 2027)
• Sales/Consumption Volume Estimation and Forecast (2020 – 2027)
• Breakdown of Revenue by Segments (2020 – 2027)
• Breakdown of Production by Segments (2020 – 2027)
• Breakdown of Sales Volume by Segments (2020 – 2027)
• Gross Margin and Profitability Analysis of Companies
• Business Trend and Expansion Analysis
• Import and Export Analysis
Osteoporosis Drugs Market Segmentation
Product Outlook (Revenue, USD Million, 2020 - 2027)
• Antiresorptive Drugs
• Anabolic Drugs
Application Outlook (Revenue, USD Million, 2020 - 2027)
Country (Revenue, USD Million, 2020 - 2027)
• United States
• United Kingdom
• South Korea
• Middle East
• Rest of World
Osteoporosis Drugs Market Companies
• Eli Lilly
• Novo nordisk
• F. Hoffmann-La Roche AG
• Radius Health
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
Please fill in the form below to Request for free Sample Report
Office Hours Mon - Sat 10:00 - 16:00
Send Us Mail email@example.com
© 2018 Market Decipher. All Rights Reserved